Event Abstract

Targeted photothermal therapy of cancer cells using folic acid-modified gold nanostars

  • 1 National Institute for Materials Science, International Center for Materials Nanoarchitectonics, Japan
  • 2 University of Tsukuba, Department of Materials Science and Engineering, Graduate School of Pure and Applied Sciences, Japan

Introduction: Development of multifunctional nanoplatforms for cancer therapy remains a great challenge. In recent years, many nanoparticles have been developed as photothermal conversion agents for photothermal therapy, such as gold nanostars (AuNSs) and nanorods (AuNRs)[1]. However, stabilization and functional modification of nanoparticles are generally required to improve their colloidal stability, biocompatibility and specificity to the target tissues.

Materials and Methods: Folic acid (FA) was conjugated with bovine serum albumin (BSA) to form BSA-FA conjugate by activating the terminal carboxylate of FA. In the growth solution, BSA-FA conjugate stabilized AuNSs (BSA-FA-AuNSs) were synthesized through the seed-mediated method. For comparison, BSA-AuNSs without FA modification (BSA-AuNSs) were also prepared by the same method by using BSA instead of BSA-FA conjugate.

Results and Discussion: The BSA-FA-AuNSs showed star-like structure with mean size of 100.0 ± 24.4 nm confirmed by TEM (Figure 1a). The prepared NSs showed improved dispersibility and colloidal stability in water, phosphate buffered saline buffer and cell culture medium. The strong absorption property at near-infrared (NIR) regions enabled the increasing temperature of AuNSs under laser irradiation (Figure 1b). The BSA-FA-AuNSs showed not only low cytotoxicity in the range of concentrations used, but also targeting specificity to the FA receptor-overexpressed cancer cells, which was confirmed by cellular uptake. The BSA-FA-AuNSs displayed much better killing efficiency to HeLa cells under NIR irradiation compared with BSA-AuNSs without FA modification (Figure 1c).The BSA-FA-AuNSs displayed a higher photothermal conversion efficiency than other previous reported AuNSs[2]. The high affinity of BSA-FA-AuNSs to HeLa cells resulted in the higher cellular uptake and better killing efficiency.

Conclusion: BSA-FA-AuNSs was successfully prepared through a facile seed-mediated growth method for targeted photothermal ablation of cancer cells. Taking into consideration of the numerous functional groups and drug loading capacity of BSA, the BSA-FA-AuNSs may be developed into multifunctional theranostic agents for diagnosis and treatment of different cancer.

This work was supported by the World Premier International Research Center Initiative (WPI) of Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan

References:
[1] Jo H, Youn H, Lee S, Ban C. Ultra-effective photothermal therapy for prostate cancer cells using dual aptamer-modified gold nanostars. J Mater Chem B. 2014;2:4862-4867.
[2] Barbosa S, Topete A, Alatorre-Meda M, Villar-Alvarez EM, Pardo A, Alvarez-Lorenzo C, et al. Targeted Combinatorial Therapy Using Gold Nanostars as Theranostic Platforms. J Phys Chem C. 2014;118:26313-26323.

Keywords: nanoparticle, Surface modification, theranostic, targeting delivery

Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016.

Presentation Type: Poster

Topic: Biomimetic materials

Citation: Li J, Cai R, Naoki K and Chen G (2016). Targeted photothermal therapy of cancer cells using folic acid-modified gold nanostars. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.02778

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 27 Mar 2016; Published Online: 30 Mar 2016.